PolyPid Ltd.

PolyPid Ltd. is a global clinical-stage bio-pharmaceutical company with a focus on developing, manufacturing, and commercializing novel therapies for surgical outcomes. The company's PLEX (Polymer-Lipid Encapsulation matriX) technology is designed to provide controlled and continuous delivery of medications at surgical sites, targeting localized medical conditions such as infection, pain, inflammation, and cancer. Their innovative approach aims to improve patient outcomes, particularly in addressing Surgical Site Infections (SSIs), a prevalent type of Healthcare Acquired Infections (HAIs). With a commitment to reducing overall surgical infection rates, including those due to antibiotic-resistant bacteria, PolyPid's efforts align with addressing public health challenges as identified by the FDA. Founded in 2008 and headquartered in Israel, the company received a significant $16.20MPost-IPO Equity investment on 04 January 2024 from DAFNA Capital Management, LLC and Rosalind Capital Partners. Trading under the symbol PYPD on NASDAQ, PolyPid is positioned to make a significant impact in the biopharma, biotechnology, health care, and pharmaceutical industries.